Panelists discuss how systemic therapy plays a crucial role in embolization-eligible hepatocellular carcinoma (HCC), ...

Hepatocellular carcinoma (HCC) represents about 80 to 90% of cases of primary liver cancer. On a global level, 905,700 new cases and 830,200 deaths were registered in 2020, according to the World ...

Immunotherapy has revolutionised the treatment of advanced hepatocellular carcinoma, starting with atezolizumab–bevacizumab superseding sorafenib in the first line. But how have other areas of care ...

Transplantation combined with immunotherapy to cure liver cancer. Hepatocellular carcinoma (HCC) is the most common type of liver cancer in Switzerland and worldwide. Immunotherap ...

An expert discusses how, for advanced unresectable hepatocellular carcinoma (uHCC), clinicians monitor treatment efficacy ...

An interval of fewer than 30 days between the last immunotherapy dose and the liver transplant increases the rejection risk more than 21-fold. Extending the interval to 30-50 days reduces the risk, ...

Previously-untreated patients with hepatocellular carcinoma (HCC), a common form of liver cancer, will have an immunotherapy-based treatment option after NICE gave the nod to NHS funding of Roche ...

Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...

Teclison, Inc., a clinical-stage oncology company dedicated to advancing immunotherapeutic treatments for solid tumors, today announced that Ray Lee, chief executive officer and co-founder of Teclison ...